Lancet Study Highlights Melioidosis Disease Burden and Diagnostic Gaps in India

A multicentre study published in The Lancet Global Health has drawn attention to the clinical burden and underdetection of melioidosis, a serious bacterial infection, across India. Investigating high-risk hospitalised adults at 15 tertiary-care centres between January 2023 and December 2025, researchers detected culture-confirmed infections in 262 of 2,953 patients (8.9%). Notably, 50 of these confirmed cases (19.1%) resulted in hospital deaths, highlighting significant mortality risks and the necessity of targeted surveillance.

Relevance for UPSC Aspirants

For Civil Services candidates, the study intersects with general science, infectious disease epidemiology, and public health infrastructure under General Studies Paper 2 and Paper 3. It highlights the challenges of diagnosing environmental bacterial pathogens, secondary infections in individuals with non-communicable diseases such as diabetes, and the need for institutional surveillance systems under national health frameworks.

Pathogen Characteristics and Clinical Manifestations

Melioidosis is caused by Burkholderia pseudomallei, a bacterium present in soil and surface water across tropical and subtropical environments. Human infection predominantly occurs when contaminated mud or water enters through cuts, abrasions, or via the inhalation of dust and water droplets, whereas person-to-person transmission is exceptionally rare. Key aspects include:

• Vulnerability Factors: Uncontrolled diabetes represents the foremost predisposing condition, alongside chronic liver, lung, and kidney ailments, as well as heavy alcohol use.
• Symptom Profile: The disease mimics conditions like tuberculosis, exhibiting severe pneumonia, bloodstream infections, septic arthritis, and deep-seated abscesses in organs such as the spleen and liver.
• Diagnostic Hurdles: Conventional automated microbiological systems, such as VITEK 2, frequently misidentify the organism as other bacteria, including Acinetobacter baumannii complex. Confirmatory testing requires specialized culture protocols, mass spectrometry, or molecular assays.

Treatment Guidelines and Health Interventions

According to technical guidance from the National Centre for Disease Control (NCDC) in its 2025 zoonotic diseases manual, clinical management requires a two-phase antimicrobial approach: an intensive intravenous regimen utilizing ceftazidime or meropenem, followed by prolonged oral eradication using trimethoprim-sulfamethoxazole to curb high rates of recurrence. With no licensed vaccine currently available, public health experts emphasize structured national surveillance, laboratory capacity-building, and protective gear for outdoor workers to prevent exposure.